Key result
A single 6-mg oral dose of spirapril achieved a peak plasma concentration of 30 ng/ml, which was required to normalize pulmonary capillary wedge pressure and brachial blood flow in severe CHF.
Why the study?
Does a single oral dose of spirapril affect plasma converting enzyme activity and hemodynamics in patients with severe congestive heart failure?
Population
8 patients with severe congestive heart failure (CHF)
Design
Other
Follow-up
48 hours
Authors
Loading...
Higher spiraprilat levels may be needed to normalize hemodynamics than for ACE inhibition in severe CHF; leaves open optimal dosing.
Does a single oral dose of spirapril affect plasma converting enzyme activity and hemodynamics in patients with severe congestive heart failure?
In severe CHF, higher plasma concentrations of spiraprilat are required to normalize hemodynamics compared to the concentration needed for near-maximal ACE inhibition.
Bellissant et al. (1997) studied severe congestive heart failure (CHF) (n=8). Spirapril was evaluated on Plasma converting enzyme activity (PCEA), pulmonary capillary wedge pressure (PCWP), and brachial blood flow (BBF). A single 6-mg oral dose of spirapril achieved a peak plasma concentration of 30 ng/ml, which was required to normalize pulmonary capillary wedge pressure and brachial blood flow in severe CHF.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: